 | • レポートコード：MRC2303I0027 • 出版社/出版日：Mordor Intelligence / 2023年1月23日 • レポート形態：英文、PDF、114ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥712,500 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,312,500 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社の本調査レポートでは、世界の円偏光二色性分光器市場規模が、予測期間中に年平均6.2%で成長すると予測しています。本レポートは、円偏光二色性分光器の世界市場について調べ、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、製品別（直線偏光光源、円偏光光源、複数光源）分析、エンドユーザー別（医薬品産業、政府＆民間研究機関、その他）分析、地域別（アメリカ、カナダ、メキシコ、ドイツ、イギリス、フランス、イタリア、スペイン、中国、日本、インド、オーストラリア、韓国、中東、南アフリカ、ブラジル、アルゼンチン）分析、競争状況、市場機会・将来の動向などを以下の構成でまとめています。また、Jasco、Applied Photophysics Ltd.、On-Line Instrument Systems, Inc. (Olis)、Bruker、Bio-Logic Science Instrument, Inc、Analytik Jena AG、A.KRUSS Optronic GmbH、Spectrisなどの企業情報が含まれています。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の円偏光二色性分光器市場規模：製品別 - 直線偏光光源の市場規模 - 円偏光光源の市場規模 - 複数光源の市場規模 ・世界の円偏光二色性分光器市場規模：エンドユーザー別 - 医薬品産業における市場規模 - 政府＆民間研究機関における市場規模 - その他エンドユーザーにおける市場規模 ・世界の円偏光二色性分光器市場規模：地域別 - 北米の円偏光二色性分光器市場規模 アメリカの円偏光二色性分光器市場規模 カナダの円偏光二色性分光器市場規模 メキシコの円偏光二色性分光器市場規模 … - ヨーロッパの円偏光二色性分光器市場規模 ドイツの円偏光二色性分光器市場規模 イギリスの円偏光二色性分光器市場規模 フランスの円偏光二色性分光器市場規模 … - アジア太平洋の円偏光二色性分光器市場規模 中国の円偏光二色性分光器市場規模 日本の円偏光二色性分光器市場規模 インドの円偏光二色性分光器市場規模 … - 中東/南米の円偏光二色性分光器市場規模 南アフリカの円偏光二色性分光器市場規模 ブラジルの円偏光二色性分光器市場規模 アルゼンチンの円偏光二色性分光器市場規模 … - その他地域の円偏光二色性分光器市場規模 ・競争状況 ・市場機会・将来の動向 |
The circular dichroism spectrometers market is expected to register a CAGR of 6.2% over the forecast period.
The COVID-19 pandemic is expected to have a significant impact on the market as initially due to the lockdown restrictions imposed by the countries to control the spread of the virus, the research and development activities were impacted but after that with the growing severity of the pandemic, very intensive research and development activities were started to find a cure for SARS-CoV-2 virus infection in which circular dichroism spectrometers were also used. For instance, according to the research study published in August 2020, titled “Computed Optical Spectra of SARS-Cov-2 Proteins”, three types of optical spectra of SARS-CoV-2 proteins were analyzed: far-ultraviolet (UV) electronic circular dichroism (CD), near-UV CD and infrared (IR) spectra in the amid region and it was observed that the aromatic residue local conformational changes are detectable in the near-UV CD spectrum. According to the study results, it may detect slightly varied tertiary structure characteristics in various protein models; while in the absence of other experimental or computational data, near-UV CD spectra are challenging to interpret. However, calculated spectra might match the protein’s true conformational distribution in solution when paired with a collection of molecular dynamics snapshots. Therefore, the outbreak of the pandemic increased the research activities which in turn propelled the demand for circular dichroism spectrometers. Thus, the market witnessed considerable growth during the pandemic.
The increasing popularity of biologics and increasing investments by private and public sectors are the major factors propelling the market growth. The circular dichroism spectrometers are used in the study of molecular structure and chiral activities of biomolecules, their use is expected to increase with the growing popularity and usage of biopharmaceuticals or biologics (for example, vaccines, gene and cellular therapies, fusion proteins, insulin, interferon, and monoclonal antibody (mAb) among others) that are used in the treatment of various chronic and rare diseases. For instance, according to the April 2022 report of the American Cancer Society, biologics are used in the treatment of cancer in many ways and are being used widely for the treatment. Furthermore, in June 2022, Amgen Inc. received approval for RIABNI (rituximab-arrx), a biosimilar to Rituxan, from the United States Food and Drug Administration for adults with moderate to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies in combination with methotrexate. Hence, the growing usage of biologics drugs and their potential in treating various diseases is expected to increase intensive research and development activities, where circular dichroism spectrometers may be in the analysis of biomolecules and thus, the demand for circular dichroism spectrometers is expected to increase over the forecast period that is expected to boost growth in the studied market.
Moreover, the growing research and development activities along with new investments in the area by the government as well as private entities are expected to fuel growth in the circular dichroism spectrometers market over the forecast period. For instance, in August 2022, Innovent Biologics of China and Paris-based Sanofi would invest USD 2.42 billion in the biopharma group to jointly develop two cancer drugs in China. As per the Innovent Biologics, SAR408701, or tusamitamab ravtansine, would be used to treat lung, gastric and other cancers, while SAR444245, or non-alpha IL-2, was under phase-II studies for skin cancer, head, and neck tumors, among others. In addition to this, the other business expansion initiative by the companies in the biologics area such as expansion, mergers, acquisitions, and collaborations are further expected to fuel growth in the bioprocess containers market over the forecast period. For instance, in June 2022, the Rare Disease division of AstraZeneca, Alexion, will spend about EUR 65 million to expand its manufacturing capabilities in Ireland, and over the next 18 months, the investment will be used by the company to build up its biologics manufacturing capacity and increase research and development initiatives in the country. Therefore, due to the above-mentioned factors, the demand for circular dichroism spectrometers is expected to increase, thereby considerable market growth is anticipated over the forecast period.
However, the lack of skilled professionals is expected to restrain the growth of the circular dichroism spectrometers market over the forecast period.
Circular Dichroism Spectrometers Market Trends
Pharmaceutical Industry is Expected to Witness Growth Over the Forecast Period
The pharmaceutical industry is one of the largest end-users of various analytical instruments as they are intensively involved in the research and development activities of biologics and other drug molecules hence, the use of circular dichroism spectrometers is expected to increase among the pharmaceutical companies and the market is expected to grow. For instance, according to the November 2021 report of the Office for National Statistics (ONS) of the United Kingdom, the amount spent on research and development annually in the pharmaceutical industry in the United Kingdom has increased 6% to an all-time high of GBP 5.02 billion (about USD 6.76 billion), which is about 18.6 of the total research and development spending of the United Kingdom.
Moreover, the growing investment in drug research and development activities by the key market players in the area is further expected to increase the demand for circular dichroism spectrometers which is expected to boost the segment’s growth. For instance, in May 2022, Pfizer Inc. launched global drug research and development center at the Indian Institute of Technology (IIT) – Madras Research Park in Chennai, India with an investment of about USD 20.0 million. Therefore, due to the aforementioned factors, the pharmaceutical industry is expected to hold a significant share in the studied market over the forecast period.
Therefore, owing to the above mentioned factors considerable segment growth is anticipated over the forecast period.
North America is Expected to Dominate the Circular Dichroism Spectrometers Market Over the Forecast Period
North America is expected to dominate the overall circular dichroism spectrometers market, over the forecast period. The growth is due to factors due to the rising popularity of biologics drugs in the region and high research and development expenditure. For instance, in May 2022, Abevmy, which is jointly developed by Biocon Biologics and Viatris was approved by Health Canada across four oncology indications. Abevmy is a recombinant humanized monoclonal antibody that selectively binds to human vascular endothelial growth factor (VEGF) and neutralizes its biological activity. Similarly, in March 2021, the Government of Canada provided funding of USD 415 million to Sanofi Pasteur Limited (Sanofi) in building an end-to-end influenza vaccine manufacturing facility in Toronto, and apart from this, Sanofi will invest about USD 455 million for different activities in the facility.
Key product launches, high concentration of market players or manufacturer’s presence, and acquisition & partnerships among major players, and increasing research and development investments in the United States are some of the factors driving the growth of the circular dichroism spectrometers market in the country. For instance, the research and development expenditure of Pfizer increased from USD 9.4 billion to USD 13.8 billion in 2021 and as Pfizer is involved in the research and development of various biologics, the demand for circular dichroism spectrometers is expected to increase in the United States.
Therefore, due to the above-mentioned factors, the North American region is expected to hold a significant market share in the circular dichroism spectrometers market over the forecast period.
Circular Dichroism Spectrometers Market Competitor Analysis
The circular dichroism spectrometers market is consolidated and consists of a few major players. The competitive landscape includes an analysis of a few international as well as local companies which hold the market shares and are well known including Jasco, Applied Photophysics Ltd., On-Line Instrument Systems, Inc. (Olis), Bruker, and Bio-Logic Science Instrument, Inc. among others.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Defination
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Popularity of Biologics
4.2.2 Increasing Investments by Private and Public Sectors
4.3 Market Restraints
4.3.1 Requirement of Specialized Infrastructure and Skilled Operators
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value – USD Million)
5.1 By Product
5.1.1 Linearly Polarized Light Sources
5.1.2 Circularly Polarized Light Sources
5.1.3 Multiple Light Sources
5.2 By End User
5.2.1 Pharmaceutical Industry
5.2.2 Government and Private Research Organizations
5.2.3 Others
5.3 Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South Korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle-East
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle-East
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Jasco
6.1.2 Applied Photophysics Ltd.
6.1.3 On-Line Instrument Systems, Inc. (Olis)
6.1.4 Bruker
6.1.5 Bio-Logic Science Instrument, Inc
6.1.6 Analytik Jena AG
6.1.7 A.KRUSS Optronic GmbH
6.1.8 Spectris
7 MARKET OPPORTUNITIES AND FUTURE TRENDS